FTC Scrutiny Chills Medtech M&A Market

Medtech M&A has been a bit sluggish this year, and the Federal Trade Commission could be to blame.

In a recent analyst report, Neehdam & Co.'s Mike Matson noted that both the number of medtech M&A deals and dollar volume of deals is likely to decrease again in 2023.

"We think that a challenging antitrust regulatory environment is the biggest factor weighing on M&A," Matson wrote in the June 30 report, which also cites high interest rates and continued economic uncertainty as factors behind the trend.